Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Narrative review discusses immune checkpoint inhibitors in lung cancer patients
New Hope for Lung Cancer Patients
This narrative review examines immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 and CTLA-4 inhibitors, for patients with lung cance…
Lung cancer patients now have a fighting chance as new medicines help the body's own immune system attack tumors instead of just killing cel…
Network meta-analysis of immunotherapy for persistent, recurrent, or metastatic cervical cancer
Do newer immunotherapies help people with advanced cervical cancer live longer?
This systematic review and network meta-analysis of phase III trials synthesized evidence on first-line immunotherapy regimens for persisten…
Newer immunotherapy combinations help people with advanced cervical cancer live longer and shrink tumors better than standard chemotherapy a…
Phase 3 RCT Shows Perioperative Enfortumab Vedotin and Pembrolizumab Benefit Muscle-Invasive Bladder Cancer
New Hope for Bladder Cancer Patients Who Can’t Tolerate Standard Chemo
This phase 3 randomized controlled trial enrolled 344 patients with muscle-invasive bladder cancer ineligible for cisplatin-based chemothera…
A new two-drug treatment more than doubles the odds of staying cancer-free for bladder cancer patients who can't handle standard chemo.
Narrative review explores CSF1R inhibitor potential in pediatric medulloblastoma precision immunotherapy
The Hidden Reason Children's Brain Tumors Respond So Differently to Treatment
This narrative review examines the role of CSF1R inhibitors as precision immunotherapy for pediatric medulloblastoma subtypes.
Each subtype of children's brain tumors has a unique immune fingerprint, meaning matching treatment to that specific environment could drama…
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
Case report and literature review on concurrent t-AML and LNTB treated with chemoimmunotherapy
Two Rare Diseases Strike After Lung Cancer Treatment
This case report and literature review describes the management of a 54-year-old male with locally advanced lung squamous cell carcinoma, th…
A lung cancer patient treated with chemo and immunotherapy developed two rare diseases simultaneously: a new blood cancer and tuberculosis.
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in Chinese adults with advanced biliary tract carcinoma
Could adding pembrolizumab help Chinese adults live longer with advanced biliary tract carcinoma?
This phase 3 randomized controlled trial enrolled 158 Chinese adults with advanced or unresectable biliary tract carcinoma.
A completed study in China compared adding pembrolizumab to chemotherapy for advanced bile duct cancer, tracking how long 158 adults survive…
Zanubrutinib-combined therapy in heavily treated non-GCB DLBCL: retrospective two-center cohort of 27 patients
New hope for tough lymphoma cases
A retrospective two-center cohort of 27 heavily treated patients with relapsed/refractory non-GCB DLBCL evaluated zanubrutinib-combined ther…
Combining zanubrutinib with other treatments helped 74% of patients with tough, hard-to-treat lymphoma respond after standard options failed…
Anti-PD-1 plus chemoradiotherapy improved event-free survival in MS1 subtype nasopharyngeal carcinoma patients compared with chemoradiotherapy alone
New Test Picks Who Wins From Cancer Drug
This review analyzed pooled data from two Phase III randomized clinical trials involving 407 patients with locoregionally advanced nasophary…
A new test identifies which nasopharyngeal cancer patients will survive longer when adding immunotherapy to standard radiation and chemother…
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Exploratory RCT finds in situ vaccine plus PD-1 with immunoradiotherapy shows response in advanced hepatic malignancies
New Vaccine Combo Shrinks Liver Tumors Safely
An exploratory RCT of 18 patients with advanced hepatic malignancies compared in situ vaccine FOLactis plus PD-1 antibody combined with eith…
A new vaccine combo shrinks liver tumors safely without the severe side effects usually caused by strong cancer drugs.